Barcelona, [July 2nd, 2025] — The Board of Directors of Peptomyc S.L., a pioneering biotech company developing innovative cancer therapies targeting the MYC oncoprotein, is pleased to announce a strategic leadership transition aimed at accelerating the company’s business development and clinical expansion efforts.
Effective July 2nd, 2025, Jesus Martin Garcia will assume the role of Chief Executive Officer (CEO). Jesus brings a strong track record in business development, strategic partnerships, and company scaling across the biotech and pharmaceutical sectors. His leadership is expected to reinforce Peptomyc’s corporate growth and partnering strategy as the company advances its clinical pipeline and explores new therapeutic opportunities, including its promising radioligand program.
You can read the full press release here:
https://www.peptomyc.com/peptomyc-announces-leadership-transition-to-support-next-phase-of-growth/